The cardenolide UNBS1450, which has been tested in a phase I clinical trial against NSCLC, can deactivate nuclear factor-κB (NF-κB)-mediated cytoprotective effects in human NSCLC. The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.